

## Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* 2022, 14, 374

Bailey, Simon; André, Nicolas; Gandola, Lorenza; Massimino, Maura; Wheatley, Keith; Gates, Simon; Homer, Victoria; Rutkowski, Stefan; Clifford, Steven C.

DOI:

[10.3390/cancers16061084](https://doi.org/10.3390/cancers16061084)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Bailey, S, André, N, Gandola, L, Massimino, M, Wheatley, K, Gates, S, Homer, V, Rutkowski, S & Clifford, SC 2024, 'Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* 2022, 14, 374', *Cancers*, vol. 16, no. 6, 1084. <https://doi.org/10.3390/cancers16061084>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Correction

# Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* 2022, 14, 374

Simon Bailey <sup>1,2,\*</sup>, Nicolas André <sup>3,4,†</sup>, Lorenza Gandola <sup>5,†</sup>, Maura Massimino <sup>6,‡</sup>, Keith Wheatley <sup>7</sup>, Simon Gates <sup>7</sup>, Victoria Homer <sup>7</sup>, Stefan Rutkowski <sup>8,‡</sup> and Steven C. Clifford <sup>2,‡</sup>

<sup>1</sup> Great North Children's Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK

<sup>2</sup> Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK; [steve.clifford@newcastle.ac.uk](mailto:steve.clifford@newcastle.ac.uk)

<sup>3</sup> Pediatric Hematology and Oncology Department, Hôpital Pour Enfants de La Timone, AP-HM, 13005 Marseille, France; [nicolas.andre@ap-hm.fr](mailto:nicolas.andre@ap-hm.fr)

<sup>4</sup> Centre de Recherche en Cancérologie de Marseille, SMARTc Unit, Inserm U1068, Aix Marseille University, 13005 Marseille, France

<sup>5</sup> Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; [lorenza.gandola@gmail.com](mailto:lorenza.gandola@gmail.com)

<sup>6</sup> Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; [maura.massimino@istitutotumori.mi.it](mailto:maura.massimino@istitutotumori.mi.it)

<sup>7</sup> Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT, UK; [k.wheatley@bham.ac.uk](mailto:k.wheatley@bham.ac.uk) (K.W.); [s.gates@bham.ac.uk](mailto:s.gates@bham.ac.uk) (S.G.); [v.s.homer@bham.ac.uk](mailto:v.s.homer@bham.ac.uk) (V.H.)

<sup>8</sup> Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [s.rutkowski@uke.de](mailto:s.rutkowski@uke.de)

\* Correspondence: [simon.bailey@ncl.ac.uk](mailto:simon.bailey@ncl.ac.uk); Tel.: +44-1912824068

† These authors contributed equally to this work.

‡ These authors contributed equally to this work.



**Citation:** Bailey, S.; André, N.;

Gandola, L.; Massimino, M.; Wheatley,

K.; Gates, S.; Homer, V.; Rutkowski, S.;

Clifford, S.C. Correction: Bailey et al.

Clinical Trials in High-Risk

Medulloblastoma: Evolution of the

SIOP-Europe HR-MB Trial. *Cancers*

2022, 14, 374. *Cancers* 2024, 16, 1084.

[https://doi.org/10.3390/](https://doi.org/10.3390/cancers16061084)

[cancers16061084](https://doi.org/10.3390/cancers16061084)

Received: 12 January 2024

Accepted: 2 February 2024

Published: 7 March 2024



**Copyright:** © 2024 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the Creative Commons

Attribution (CC BY) license ([https://](https://creativecommons.org/licenses/by/4.0/)

[creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/)

[4.0/](https://creativecommons.org/licenses/by/4.0/)).

## Missing Funding

In the original publication [1], the funder Cancer Research UK, A2524 was not included.

## Addition of Authors

Keith Wheatley, Simon Gates, and Victoria Homer were not included as authors in the original publication. The reason we would like to add the authors is that the statistical element of the trial and the trial design were in a large part done by the statistical authors and the team were necessary for the running of the trial. The corrected Author Contributions Statement appears here.

**Author Contributions:** Conceptualization, S.B., N.A., L.G., M.M., K.W., S.R. and S.C.C.; methodology, K.W., S.G. and V.H.; project administration, S.G. and V.H.; resources, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—original draft preparation, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—review and editing, S.B., N.A., L.G., M.M., S.R. and S.C.C. All authors have read and agreed to the published version of the manuscript.

## Additional Affiliation

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT, UK; [k.wheatley@bham.ac.uk](mailto:k.wheatley@bham.ac.uk) (K.W.); [s.gates@bham.ac.uk](mailto:s.gates@bham.ac.uk) (S.G.); [v.s.homer@bham.ac.uk](mailto:v.s.homer@bham.ac.uk) (V.H.)

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

---

## Reference

1. Bailey, S.; André, N.; Gandola, L.; Massimino, M.; Rutkowski, S.; Clifford, S.C. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* **2022**, *14*, 374. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.